{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:32:49Z","timestamp":1783114369155,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.yebeh.2024.110158","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T10:56:32Z","timestamp":1732877792000},"page":"110158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Trends in antiseizure medication prescription in Idiopathic generalized epilepsy over the last 10\u00a0years"],"prefix":"10.1016","volume":"163","author":[{"given":"Iker","family":"Elosua-Bayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-7929","authenticated-orcid":false,"given":"Laura","family":"Abraira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-1237","authenticated-orcid":false,"given":"Elena","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-9889","authenticated-orcid":false,"given":"Sof\u00eda","family":"Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-5309","authenticated-orcid":false,"given":"Daniel","family":"Campos-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"L\u00f3pez-Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estevo","family":"Santamarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Salas-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yebeh.2024.110158_b0005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/epi.17236","article-title":"ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions","volume":"63","author":"Hirsch","year":"2022","journal-title":"Epilepsia junio de"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110158_b0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia Marzo de"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110158_b0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/aian.aian_888_21","article-title":"Current concepts in the management of idiopathic generalized epilepsies","volume":"25","author":"Rathore","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"issue":"11","key":"10.1016\/j.yebeh.2024.110158_b0020","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1212\/WNL.33.11.1474","article-title":"Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures","volume":"33","author":"Wilder","year":"1983","journal-title":"Neurol noviembre de"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110158_b0025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1528-1157.1988.tb03759.x","article-title":"Valproate in the treatment of absence epilepsy in children: a study of dose-response relationships","volume":"29","author":"Braathen","year":"1988","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110158_b0030","first-page":"75","article-title":"The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies","volume":"75","author":"Nicolson","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry enero de"},{"issue":"9566","key":"10.1016\/j.yebeh.2024.110158_b0035","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.yebeh.2024.110158_b0040","unstructured":"Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet Lond Engl. 10 de abril de 2021;397(10282):1375-86."},{"key":"10.1016\/j.yebeh.2024.110158_b0045","doi-asserted-by":"crossref","unstructured":"Christensen J, Gr\u00f8nborg TK, S\u00f8rensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 24 de abril de 2013;309(16):1696-703.","DOI":"10.1001\/jama.2013.2270"},{"issue":"7","key":"10.1016\/j.yebeh.2024.110158_b0050","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia julio de"},{"key":"10.1016\/j.yebeh.2024.110158_b0055","unstructured":"European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. [Internet]. Disponible en: https:\/\/www.ema.europa.eu\/en\/ documents\/referral\/valproate-article-31-referral-new-measu res-avoid-valproate-exposure-pregnancy-endorsed_en-0."},{"key":"10.1016\/j.yebeh.2024.110158_b0060","article-title":"Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy","volume":"102","author":"Fonseca","year":"2020","journal-title":"Epilepsy Behav EB enero de"},{"issue":"11","key":"10.1016\/j.yebeh.2024.110158_b0065","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.yebeh.2024.110158_b0070","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia septiembre de"},{"key":"10.1016\/j.yebeh.2024.110158_b0075","doi-asserted-by":"crossref","unstructured":"Torres-Ferr\u00fas M, Toledo M, Gonz\u00e1lez-Cuevas M, Ser\u00f3-Ballesteros L, Santamarina E, Raspall-Chaure M, et al. [Aetiology and treatment of epilepsy in a series of 1,557 patients]. Rev Neurol. 1 de octubre de 2013;57(7):306-12.","DOI":"10.33588\/rn.5707.2013214"},{"key":"10.1016\/j.yebeh.2024.110158_b0080","unstructured":"European Medicines Agency. EMA review of data on paternal exposure to valproate [Internet]. Disponible en: https:\/\/www.ema.europa.eu\/en\/news\/ema-review-data-paternal-exposure-valproate."},{"key":"10.1016\/j.yebeh.2024.110158_b0085","doi-asserted-by":"crossref","unstructured":"Christensen J, Trabjerg BB, Dreier JW. Valproate Use During Spermatogenesis and Risk to Offspring. JAMA Netw Open. 4 de junio de 2024;7(6):e2414709.","DOI":"10.1001\/jamanetworkopen.2024.14709"},{"key":"10.1016\/j.yebeh.2024.110158_b0090","doi-asserted-by":"crossref","unstructured":"Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Epilepsy Group, editor. Cochrane Database Syst Rev [Internet]. 8 de febrero de 2019 [citado 29 de marzo de 2024]; Disponible en: https:\/\/doi.wiley.com\/10.1002\/14651858.CD003032.pub4.","DOI":"10.1002\/14651858.CD003032.pub4"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110158_b0095","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/pediatric13040078","article-title":"Therapeutic Options for Childhood Absence Epilepsy","volume":"13","author":"Rinaldi","year":"2021","journal-title":"Pediatr Rep"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110158_b0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ane.13389","article-title":"Levetiracetam as first-line monotherapy for Idiopathic Generalized Epilepsy in women","volume":"143","author":"Ballv\u00e9","year":"2021","journal-title":"Acta Neurol Scand abril de"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110158_b0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1684\/j.1950-6945.2005.tb00127.x","article-title":"Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes","volume":"7","author":"Di Bonaventura","year":"2005","journal-title":"Epileptic Disord Int Epilepsy J Videotape septiembre de"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110158_b0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res septiembre de"},{"issue":"8","key":"10.1016\/j.yebeh.2024.110158_b0115","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110158_b0120","article-title":"Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial","volume":"157","author":"Tabrizi","year":"2019","journal-title":"Epilepsy Res noviembre de"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110158_b0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eplepsyres.2009.02.016","article-title":"Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies","volume":"85","author":"Rosenfeld","year":"2009","journal-title":"Epilepsy Res julio de"},{"issue":"10","key":"10.1016\/j.yebeh.2024.110158_b0130","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry octubre de"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:00:31Z","timestamp":1739458831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024005407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"alternative-id":["S1525505024005407"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110158","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in antiseizure medication prescription in Idiopathic generalized epilepsy over the last 10\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110158"}}